Yüklüyor......

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition

RATIONALE: Advanced hepatocellular carcinoma (HCC) remains a deadly disease in part due to decades of limited therapeutic options. With recent advances in our understanding of the tumor biology, several promising treatment strategies involving targeted and immunotherapies have emerged. However, enha...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Medicine (Baltimore)
Asıl Yazarlar: Swed, Brandon, Ryan, Kara, Gandarilla, Omar, Shah, Manish A., Brar, Gagandeep
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2021
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8238293/
https://ncbi.nlm.nih.gov/pubmed/34160456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000026471
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!